For Immediate Release
Chicago, IL – April 2, 2012 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Supervalu Inc. (SVU - Free Report) , Medco Health Solutions , Express Scripts Inc. ( (ESRX - Free Report) , Walgreen Company and PACCAR Inc. ( (PCAR - Free Report) .
Get the most recent insight from Zacks Equity Research with the free Profit from the Pros newsletter: https://at.zacks.com/?id=5513
Here are highlights from Friday’s Analyst Blog:
Medco-ESRX Deal Irks Supervalu
The leading grocery chain and heavyweight pharmacy retailer Supervalu Inc. (SVU - Free Report) is now an addition to the list of many pharmacy companies for whom the takeover of Medco Health Solutions by Express Scripts Inc. ( (ESRX - Free Report) did not go down well. Supervalu made its view public along with other retail giants urging the takeover would leave "only two significant competitors in a highly concentrated industry."
The National Association of Chain Drug Stores (of which Supervalu is a member), the National Community Pharmacists Association, and few retail pharmacy companies have filed a lawsuit at US District Court for the Western District of Pennsylvania appealing that the merger should be stopped.
Express Scripts wants to takeover Medco Health Solutions for $29.0 billion. The two pharmacy chains are big players in the field of Pharmacy Benefit.
Given the large purchasing power, the Pharmacy Benefit Managers (PBM) negotiate and reduce employers, government agencies and other clients’ spending on prescription drugs.
If the merger takes place, St. Louis-based Express Scripts and New Jersey-based Medco would create the largest U.S. PBM, controlling prescriptions of more than one in three Americans. Thus, the pharmacy groups are worried that the merger will hurt several retail pharmacy chains, specialty chains and huge employers who need pharmacy benefits.
We note, earlier this year that another retail bigwig Walgreen Company had refrained from renewing its license with Express Scripts.
Therefore, customers who were registered with Express Script had to refill their prescriptions at new pharmacies or pay for them out of their own pocket.
Supervalu’s Shop n Save with 50 stores in Illinois and Missouri, and 34 pharmacies planned to hire more workers and enhance its pharmacy services to welcome patients with Express Scripts prescription plans.
It has urged the Express Script customers to transfer prescriptions well ahead of time, as then the pharmacist at the Shop n Save stores can arrange for the medicines in advance.
Supervalu holds a Zacks #3 Rank that implies a short term Hold Rating.
PACCAR Launches New Trucks
With a view to improving its product lines, PACCAR Inc. ( (PCAR - Free Report) has launched high technology aerodynamic trucks at the Mid-America Trucking Show in Louisville, Kentucky. It took nearly 4 years and $400 million to launch these trucks under the Kenworth T680 and Peterbilt 579 brand names.
The trucks, powered with the company’s own fuel efficient and high horse-power diesel engines, have a cab width of 2.1 meter. These trucks form part of the heavy-duty class-8 segment and are available at low price.
In the fourth quarter of 2011, PACCAR achieved a record Class 8 retail market share of 28.1% in the U.S. and Canada. Class 8 industry retail sales in the U.S. and Canada improved 56% to 197,000 units in 2011 from 126,000 in 2010.
The company reported earnings of 91 cents per share in the quarter, up from 46 cents per share in the year-ago quarter and the Zacks Consensus Estimate of 79 cents per share. Net sales and financial service revenues in the quarter surged 58% to $4.85 billion, which is the highest quarterly revenue in the company’s history. It also exceeded the Zacks Consensus Estimate of $4.21 billion.
PACCAR expects the truck market to improve in 2012 driven by recovery in the housing market. With the improvement of the truck market and introduction of new vehicles, revenues are expected to reach higher levels in the coming quarters.
Want more from Zacks Equity Research? Subscribe to the free Profit from the Pros newsletter: https://at.zacks.com/?id=5515.
About Zacks Equity Research
Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.
Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.
Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today: https://at.zacks.com/?id=5517
Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978 by Leon Zacks. As a PhD from MIT Len knew he could find patterns in stock market data that would lead to superior investment results. Amongst his many accomplishments was the formation of his proprietary stock picking system; the Zacks Rank, which continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros at https://at.zacks.com/?id=5518.
Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
Follow us on Twitter: http://twitter.com/zacksresearch
Join us on Facebook: http://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts
Disclaimer: Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security.
Zacks Investment Research
800-767-3771 ext. 9339